10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Wednesday, August 12, 2009

Panacea Biotec Ltd:Is it a buy,hold or sell?

Scripscan:Panacea Biotec Ltd

Story:What are the longer-term prospects of Panacea Biotec? The company’s name is a bit misleading but that is no reflection on its business. Panacea Biotec has little to do with biotechnology but has an amazing ability to create new niche products. It manufactures and markets branded vaccines, pharma products and ‘biotechnology-based’ products. Its manufacturing plant for vaccines at New Delhi is pre-qualified for supply to UN agencies. The company focuses mainly on vaccines and is in the process of developing a host of new ones “employing genetic engineering and recombinant technology”. It manufactures the Hepatitis B vaccine in collaboration with CIGB, Havana, Cuba. It has several other vaccines at different phases of development, like the Anthrax vaccine and the Japanese Encephalitis vaccine. It recently entered into a joint venture with Chiron Vaccines, a US-based company, to market vaccines in India. These are just some examples of the company’s progress and growth over a period of time.With more than 150 scientists in three R&D centres in pharmaceuticals, biopharmaceuticals and vaccines, it hopes to churn out many new products.The company has created a separate division called ‘Oncotrust’ for the anti-cancer venture consisting of a team of 50 oncology specialists to market its drugs.Apart from its ongoing organic growth, the company is also targeting inorganic growth through acquisitions. It is targeting a pharmaceutical or vaccine company with manufacturing infrastructure as well as distribution and marketing reach. It had invested Rs17 crore for a 10% stake in its partner Cambridge Biostability, UK, in December 2006 and also expects to announce similar licensing tie-ups. Panacea’s sound performance is backed by its ambitious plans; this could see the stock move up smartly the moment the rupee stabilises.A great buy at dips.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner